Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The Company has two products, Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis, a therapy for primary periodic paralysis. The Company uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products. The XeriSol formulation technology is suited for peptides and small molecules that encounter formulation challenges. The XeriJect formulation technology is suited for drugs and biologics consisting of large molecules such as proteins, monoclonal antibodies, and vaccines.